There have been a few items in the news lately related to Inflammatory Bowel Disease that I thought prudent to pass along to everyone. Tysabri Update: A few weeks ago I wrote about the multiple sclerosis drug, Tysabri, being approved for use in severe Crohn's disease cases (Tysabri Appr...


Seven Common Symptoms of Ulcerative Colitis
Seven Nutrition Tips for Ulcerative Colitis Patients
Quiz: Do You Know What Your Stool is Telling You?
Six Risk Factors for Ulcerative Colitis
The Dear Doc letter was sent by Biogen Idec and Elan NOT the FDA. It was not because of new cases with liver damage (see following statement by Sandy Walsh of FDA). It was sent to bring doctors who treat MS patients current with the labelling for those who treat Crohn's. BTW, a few years ago Biogen Idec sent the same letter out to doctors warning them of liver damage from Avonex. All MS drugs have had liver toxicity problems and is NOT unique to Tysabri. In fact, the incidence for Tysabri is less than some of the other drugs.
FDA spokeswoman Sandy Walsh, however, said the letter does not reflect new cases but is simply a reiteration of a revised label the FDA approved Jan. 16 as part of the expanded use of the drug for the bowel disorder Crohn's disease. (Reporting by Kim Dixon, editing by Gerald E. McCormick)
You're correct that the letter came from Biogen and Elan, however, it was the FDA who required them to send it.
My purpose here is not to dicker over who/what, but simply to make potential Tysabri user's aware of all potential side effects when making the decision whether or not to use this drug.
Thanks for your input.